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H. van Overhagen6 and T.J. Cleveland11Sheffield Vascular Institute, Northern General Hospital, Sheffield S5 7AU, UK; 2Vascular Center Berlin,
Ev. Krankenhaus Koenigin Elisabeth, Berlin, 3Klinikum der Christian-Albrechts-Universitat zu Kiel, Kiel,
Germany; 4Department of Radiology, TweeSteden Ziekenhuis, Tilburg, The Netherlands; 5University Hospitals
Gasthuisberg, Leuven, Belgium; and 6Leyenburg Hospital, Den Haag, The NetherlandsPurpose. To investigate the short term and 6 month outcomes of a recently introduced iliac stent (the Medtronic AVE
Flexible Iliac Bridge Stent).
Method. One hundred and sixteen patients, 122 limbs from 6 European sites with atherosclerotic occlusive disease were
included if they either had a full occlusion or there was a residual gradient O10 mmHg following PTA. Clinical,
haemodynamic and Duplex outcomes were recorded to 6 months.
Results. After stent placement there was no residual stenosisO30 and 8.1% of segments had a residual resting gradient of
O10 mmHg. There were three local complications and three deaths at 30 days. Primary patency at 30 days and 6 months
was 94.1 and 82.7%. Marked clinical improvement occurred in 87.6 and 86.2% at 30 days and 6 months.
Conclusion. The Medtronic AVE iliac stent has good 30 day and 6 months outcomes supporting the effective use of this
device in occlusive disease.Keywords: Iliac artery; Stents; Follow-up study; Technology assessment; Biomedical.Introduction
Ilaic artery occlusive disease is commonly managed
using a metallic stent. The Medtronic AVE Flexible
Iliac Bridge stent is a flexible balloon expandable
stainless steel design with a CE (Conformite´ Eur-
ope´en) mark. So that 30 day and 6 month clinical
outcomes could be made available to Interventional-
ists the multi-centre European FIRST (Flexible Iliac
Bridge Stent Restenosis) study was undertaken.Patients, Materials and Methods
The only published randomised trial investigating the
efficacy of stents in iliac arteries indicated that
selective placement of stents in stenoses with aing author. Sheffield Vascular Institute, Northern
ital, Herries Road, Fourth 4C Floor, Sheffield S5 7AU,
: p.a.gaines@sheffield.ac.uk
0124+ 07 $35.00/0 q 2004 Elsevier Ltd. All rights reserresidual gradient of O10 mmHg mean following
angioplasty was as successful as stenting all lesions.1
Current practise suggests that iliac occlusions are
treated by primary stenting.2,3 These data formed the
basis of patient selection.Inclusion criteria1.vedAll patients were to have symptomatic peripheral
vascular disease thought, in part at least, to be due
to atherosclerosis affecting the iliac arteries.2. Iliac stenoses were only included into the study if,
following angioplasty, there was a residual
10 mmHg peak systolic gradient at rest, or
15 mmHg after papaverine if the resting pressure
was less than 10 mmHg.13. Occlusions of the common or external iliac artery
were treated by primary stenting.4. In each limb a maximum of two lesions could be
included in the study.5. Lesions were included from the aortic bifurcation to
inguinal ligament.Eur J Vasc Endovasc Surg 29, 124–130 (2005)
doi:10.1016/j.ejvs.2004.12.004, available online at http://www.sciencedirect.com on.
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ThRestenosis (any previous surgical or endovascular
intervention upon the target iliac vessel).2. Acute thrombosis.
3. Recent (!6 weeks) thrombolysis.
4. Ipsilateral common femoral artery occlusion.
5. Ipsilateral prosthetic femoro-popliteal or femoro-
distal graft (to avoid the potential complication of
infection following prosthetic graft puncture).Technique
All patients were taking anti-platelet therapy (aspirin
75–300 mg/day). Heparin 5000 iu was given at the
time of vascular access and continued for 24 h if the
run-off score was one or less. Run-off was scored by
summating the assessment of SFA and profunda
femoris artery (main trunk) where 2 pointsZnormal,
patent with a O50% stenosisZ1 point, and complete
occlusionZ0 points.
The Medtronic AVE Bridge Stent is CE marked and
constructed from 316L stainless steel in a sinusoidal
pattern. The stent is factory balloon mounted and
available at the time of the study in diameters from 6 to
10 mm and lengths 39 and 59 mm. Stents were to be
placed only in the iliac arteries and, therefore, kept
above the circumflex iliac arteries. At the time of
intervention the residual stenosis and pressure gra-
dient were measured following angioplasty and
following stent placement.Clinical classification and follow-up
Patients were clinically stratified using the Fontaine
classification and Rutherford category prior to treat-
ment and at 30 days and 6 months.4
The Rutherford score was used to assess the
outcome following intervention at the same time
intervals.4 Exercise treadmill testing is a scarce
commodity and, therefore, the reactive hyperaemia
test was substituted for exercise testing. Thele 1. Modified Rutherford categories
therford category Clinical description Objective
Asymptomatic Normal h
nd 2 Mild to mod claudication AP after h
Severe claudication AP after h
Ischaemic rest pain Resting A
Minor tissue loss Resting A
Major tissue loss Resting A
e conventional Rutherford categories 1 and 2 are combined as definRutherford category4 requires a completed treadmill
test and post exercise ankle pressure (AP) of
O50 mmHg for category 1, a failed test and AP
!50 mmHg for category 3, and something in-between
for category 2. The article does not provide guidance
on the classification of chronic limb ischaemia using
the hyperaemia test and ankle pressures even though
it states that hyperaemia and exercise testing are
equivalent stress tests. In order to overcome this the
Rutherford categories were altered to amalgamate
categories 1 and 2 (Table 1).
The ABI and reactive hyperaemia ABI were
performed on the index limb prior to intervention,
and at 24 h, 30 days and 6 months following
treatment. The Rutherford category and Rutherford
score was recorded prior to intervention, and
repeated at 30 days and 6 months. The stented
segment was assessed by duplex examination at 30
days and 6 months. The peak systolic velocity was
measured above the stent (PSV1) and in the stent
at the site of maximum velocity (PSV2). The peak
systolic velocity ratio was expressed as PSV2/PSV1
and was considered significant when this was
equal to or greater than 2.
Because patient mobility is determined by the
symptoms in the worst leg, the denominator for
assessing clinical outcome using Rutherford category
and score was the patient and not the individual limb.
We, therefore, refer to the assessment of the manage-
ment of the patient and not of the limb or foot etc. The
limb was used as the denominator for patency and
ABI.Statistics
Both resting and hyperaemia ABI at each time after
treatment were compared against baseline. The
mean ABI was compared using the Wilcoxon
Matched Pair Rank Test. The median Rutherford
category at each time interval following interven-
tion was compared against baseline using the
Wilcoxon Rank Sums Test.criteria
yperaemia test
yperaemiaO50 mmHg but at least 20 mmHg lower than resting
yperaemia!50 mmHg
P !40 mmHg
P !40 mmHg
P !40 mmHg
ed in the Table. AP, highest ankle pressure.
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Table 3. Pre-intervention Fontaine and Rutherford category
P. A. Gaines et al.126ResultsClassification Number of
patients (of
116)
Percentage of
known
patients (of
116)
Fontaine 1 1 0.9
IIa 65 56
IIb 43 37
III 5 4.3
IV 2 1.7
Category Number of
patients (of
116)
Percentage of
patients (of
116)
Rutherford
category
0 1 0.9
1 and 2 65 56
3 43 37
4 5 4.3
5 1 0.9
6 1 0.9Pre-intervention
One hundred and sixteen patients with atherosclerotic
iliac artery disease from six centres were recruited into
the study. There were 38 females and 78 male with an
average age of 60.7 years (range 34–86). Their risk
factors are shown in Table 2.
One hundred and fifteen patients, 121 limbs were
symptomatic. One patient, (one limb) was asympto-
matic, and should not have been recruited to the study.
The data were included for completion. The patients
clinical classification, resting ABI and hyperaemia ABI
are detailed in Tables 3 and 4. It is noted that a
significant number of patients could not tolerate the
hyperaemia test, particularly immediately following
the procedure. All patients were on anti-platelet
therapy prior to treatment.
One hundred and twenty-two limbs with 125
lesions were treated. There were 12 lesions with a
significant gradient at rest and only a 31–49% stenosis
on angiography. Ninety-four stenoses were 50–99%
and there were 12 occlusions (no data was provided on
seven lesions in seven legs). Seventy-one common and
54 external iliac lesions were treated. The stenoses had
a mean length of 22.2 mm (range 4–130 mm, SD
30.5 mm) and the occlusions had a mean length of
53.9 mm (range 5–120 mm, SD 20.3 mm). The run-off
score is demonstrated in Table 5.Peri-procedural
All patients had a residual gradient following initial
angioplasty of more than 10 mmHg at rest. Despite
this 10% of patients had a stenosis of 31–49% after
initial angioplasty (Table 5). One hundred and twenty-Table 2. Risk factors
Risk factor No. patients (% of known
patients)
Smoking
Never 11/116 (9.5)
Ex-smokers 24/116 (20.7)
CurrentO20 cigarettes per
day
23/116 (19.8)
Current!20 cigarettes per
day
58/116 (50)
Diabetes 7/116 (6)
Insulin dependant 7/116 (6)
Non-insulin dependant 14/116 (12.1)
Hypertension 52/116 (44.8)
Yes 52/116 (44.8)
Hypercholesterolaemia 39/105 (37%)
Yes 39/105 (37%)
Eur J Vasc Endovasc Surg Vol 29, February 2005seven tents were placed (one stent in 123 lesions, two
stents in two lesions). The diameter of stents used
were; 5 mm—2 stents, 6 mm—9, 7 mm—39, 8 mm—
42, 9 mm—17, 10 mm—5, (missing data 13 stents). The
residual stenosis was measured in 119 lesions from 119
iliac segments (missing data three segments). There
were no residual stenoses of O30%. The resting
gradient at completion was measured following
deployment in 98 of 122 limbs (missing data 24).
Eight limbs (8.1%) had a residual gradient of O
10 mmHg.
Only one immediate complications of the procedure
was reported (0.87%). A patient had distal embolisa-
tion to a peroneal artery, the anterior tibial artery
remained patent, and no subsequent intervention was
undertaken. The patient received 24 h heparin and
there were no adverse sequelae.
The change in resting ABI and hyperaemia ABI at
24 h are shown in Table 4. The difference in the mean
ABI compared to baseline is highly significant (p!
0.0001).30 days
At 30 days three patients (four investigated limbs) had
died. One patient died in heart failure. A second
patient died but no details were made available. A
third patient died following stent thrombosis and
distal embolisation. The left foot was amputated but
death from bronchopneumonia ensued.
There were a further three significant clinical
episodes. A patient with a necrotic toe had a planned
femoro-popliteal bypass and subsequent transmeta-
tarsal amputation following stent placement. Another
elderly patient was treated with heparin and
Table 4. ABI at rest and following reactive hyperaemia
Pre-intervention 1 Day 30 Days 6 Months
Resting ABI ABI post
hyperaemia
Resting ABI ABI post
hyperaemia
Resting ABI ABI post
hyperaemia
Resting ABI ABI post
hyperaemia
No. legs 119 102 119 89 117 111 111 98
MD 3 10 3 33 1 7 0 13
Mean ABI 0.69 0.58 0.89 0.8 0.93 0.84 0.93 0.87
% Of
patients
increase
ABIO0.1
75 75 70 72 71 78
Significance
of difference
from pre-
intervention
P!0.0001 P!0.0001 P!0.0001 P!0.0001 P!0.0001 P!0.0001
ABI, ankle brachial index; MD, missing data.
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on the same side as the femoral artery puncture. He
was re-admitted, over anti-coagulated, with an acute-
on-chronic subdural haematoma. A further patient
complained of a haematoma at the site of femoral
artery puncture. No treatment was undertaken.
The change in resting ABI, hyperaemia ABI, and
Rutherford category are demonstrated in Tables 4 and
6. The difference in the mean ABI compared to baseline
is highly significant (p!0.0001). The difference in the
median Rutherford category between baseline and 30
days is highly significant (p!0.0001).
There is marked clinical improvement as judged by
the Rutherford score (Table 7). 87.6% of patients have a
Rutherford score of 2 or 3. The iliac patency at 30 days
is 94.1% (Fig. 1).6 months
At 6 months a further four patients (four limbs) were
either terminally ill (1 pt) or had withdrawn from the
study (3 pts). There were no further adverse events.
The change in resting ABI, hyperaemia ABI, and
Rutherford category are demonstrated in Tables 4 and
6. The difference in the mean ABI compared to baseline
is highly significant (p!0.0001). The difference in the
median Rutherford category between baseline and 6
months (Table 6) is highly significant (p!0.0001).Table 5. Pre-intervention run-off score
SCORE No limbs (of 122) % Of known data
(116)
0 0 0
1 2 1.7
2 24 20.7
3 20 17.2
4 70 60.3
Missing data 6There is continued marked clinical improvement as
judged by the Rutherford score (Table 7). 86.2% of
patients maintain a score of 2 or 3. The iliac patency at
6 months is 82.7% (Fig. 1).Discussion
This study was undertaken to review the performance
of the Medtronic AVE Bridge stent and was financially
supported by Medtronic AVE. To compliment these
data the published papers were reviewed where the
performance and 6 month patency of an individual
stent could be identified. The analysis was difficult
because of heterogeneity of patients, lesions treated
and definitions of outcome. With this in mind the
comparison is shown in Table 8. It should be noted that
there are a number of arterial stents available
throughout the European Community that do not
have this clinical data available.
TheMedtronic AVE device was simple to place with
no problems of deployment, and only one peri-
procedural complication occurred (distal embolisa-
tion) that had no clinical sequelae.
The primary procedural success rate depends upon
the parameter of success used. If a residual stenosis of
less than 30% is used then the primary success was
100%. If a peak systolic residual gradient of less than
10 mmHg at the end of procedure is used then the
primary success rate was 91.9%. The results compare
favourably with other stents (Table 8).
At 30 days, there were only two further procedure
related complications. A single episode of stent
thrombosis in a patient with critical limb ischaemia
resulted in limb amputation and death from bronch-
opneumonia. One patient was over-anticoagulated for
a procedural related complication and subsequently
admitted with an acute-on-chronic subdural
haematoma.Eur J Vasc Endovasc Surg Vol 29, February 2005
Fig. 1. Stent patency.
Table 6. Change in Rutherford category
Pre-intervention 30 Days 6 Months
Rutherford cat-
egory
No. pts % No. pts % No. pts %
0 1 0.9 65 58 69 65.1
1 and 2 65 56 40 35.7 33 31.1
3 43 37 7 6.3 4 3.8
4 5 4.3 0 0 0 0
5 1 0.9 0 0 0 0
6 1 0.9 0 0 0 0
Missing data 0 4 3
Pts, patients.
P. A. Gaines et al.128These complications compare favourable when
compared against the published literature on the
performance of other stents (Table 8).
Iliac segment patency was 94.1% at 30 days andTable 7. Rutherford score at 30 days and 6 months
Rutherford score No. of patients—30
days
No. of patients—6
months
C3 84 76
C2 15 18
C1 8 6
0 5 7
K1 1 2
K2 0 0
K3 0 0
Eur J Vasc Endovasc Surg Vol 29, February 200582.7% at 6 months (Fig. 1). This is comparable with the
published data on other stent designs.
Significant clinical improvement, requiring an
increase in the Rutherford score ofC2 orC3, occurred
in 87.6% of patients at 30 days and 86.2% at 6 months
(Table 7). These outcomes are broadly in line with the
iliac patency (Fig. 1). Some improvement (an increase of
C1) was seen in a further 7.1% at 30 days and 5.5% at 6
months. Therewas slight clinical deterioration in 0.8%at
30 days and 1.8% at 6 months. No patients had a
Rutherford category of greater than 3 (severe claudica-
tion) at follow-up to 6months, and indeed 58–65%were
asymptomatic. Meaningful comparison with other
stents is not possible because of the different patient
Table 8. A comparison of stents
Stent Reference % Complications,
LZlocal,
SZsystemic
Primary success
%
30d patency
%
30dmortality
%
Primary patency
at 6 months %
Palmaz Wolf5,
Henry6, Tetteroo1,
Murphy7
LZ2.7–9.7,
SZ2.7
99–100 100 0–1.2 82–96
Wallstent Vorwerk8, Vorwerk9,
Murphy10
LZ7.4–14.3,
SZ0.7–1.5
91–98 96–100 0–2.9 88–97
Strecker Long11, Strecker12 LZ11.5–12.2,
SZ1.6
98–100 ND 0 90–97
Perflex Reekers13 LZ3 94 96 0.8 94
Medtronic AVE
Bridge
This study LZ2.6 91.9–100 94.4 2.6 82.7
ND, no data.
The Medtronic AVE Bridge Stent 129groups treated but is in line with other published data.
These improvements in symptomatology occurred
despite only 70–71% of patients having a significant
improvement in their restingABI and 72–78%having an
improvement in their reactive hyperaemia ABI. This
underlines the problems of using ABI as an index of
clinical success.
Unfortunately, there are no iliac stent standards
published by the accepted learned societies against
which to compare the outcomes of this study. The
British Society of Interventional Radiology has
recently published a report of a national audit
detailing the outcome of iliac angioplasty and stents
for 1598 segments in 1135 patients (the BIAS Study).2
Stents were used in 530 cases. In that series the
primary technical success for deploying the stent in a
stenosis was 99.6%, and a residual stenosis of greater
than 30% was identified in 18% of cases. The AVE
Bridge stent compares favourably against these data.
The BIAS study identified complications in 13.7% of
stent procedures, which included groin haematomas
in 6.9%, embolus 1.9%, extensive dissection in 2.1%,
target vessel thrombosis in 1.2% and device malfunc-
tion in 1.2% of cases. Again the Bridge stent performs
well compared to these standards.
In conclusion, the Medtronic AVE Bridge Stent is
simple to use, has a low procedural complication rate,
and good patency at 6 months providing good clinical
improvement in patients with symptoms of iliac
occlusive disease. The data from this prospective
analysis indicates that it is comparable with the
limited outcome data available on other stent designs.Acknowledgements
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